Impact of cibenzoline treatment on left ventricular remodelling and prognosis in hypertrophic obstructive cardiomyopathy
| Autor: | Shuntaro Ikeda, Mareomi Hamada, Kiyotaka Ohshima, Akiyoshi Ogimoto, Yuji Shigematsu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Cardiovascular Complication Heart failure Group A Obstructive cardiomyopathy Group B Sudden cardiac death chemistry.chemical_compound Internal medicine Hypertrophic obstructive cardiomyopathy medicine Diseases of the circulatory (Cardiovascular) system Humans Pharmacology Ventricular Remodeling business.industry Incidence (epidemiology) Left ventricular function Imidazoles Original Articles Myocardial hypertrophy Cardiomyopathy Hypertrophic medicine.disease Prognosis chemistry Cibenzoline RC666-701 Cardiology Original Article Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents |
| Zdroj: | ESC Heart Failure ESC Heart Failure, Vol 8, Iss 6, Pp 4832-4842 (2021) |
| ISSN: | 2055-5822 |
| Popis: | Aims This study aimed to elucidate the long‐term effect of cibenzoline therapy on cardiovascular complications and prognosis in patients with hypertrophic obstructive cardiomyopathy (HOCM). Methods and results Eighty‐eight patients with HOCM were treated with cibenzoline (Group A), and 41 patients did not receive cibenzoline (Group B). The changes in left ventricular (LV) remodelling, incidences of cardiovascular complications and deaths, were examined. The mean follow‐up period was 15.8 ± 5.6 years in Group A and 17.8 ± 7.2 years in Group B. In Group A, the LV pressure gradient (LVPG) decreased immediately after treatment, and the reduction was maintained throughout the study. In Group B, the LVPG decreased gradually according to the deterioration of LV function. LV reverse remodelling was confirmed in Group A, and LV remodelling advanced in Group B. In Group A, the incidence of each cardiovascular complication was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text